maritide glp-1 Amgen's obesity drug may help patients keep the weight off GLP-1-based therapies for diabetes, obesity

Point of care ultrasonography can be used to assess risks in patients who do not follow dietary restrictions and in patients who describe gastrointestinal symptoms on the day of the procedure

Emerging research on melanocortin-4 receptor (MC4R) agonists combined with GLP-1/GIP agonists has shown promise for enhanced weight loss and prevention of weight regain, potentially addressing the needs of patients who plateau on current monotherapy [53]

However, long-term registry studies, cardiovascular outcome trials, and recent meta-analyses provide a more reassuring picture

No class of medication has gotten more buzz in recent years than the glucagon-like peptide-1 (GLP-1) receptor agonist, better known by the brand names Ozempic, Wegovy, Zepbound or the generic name semaglutide or tirzepatide